When people have Alzheimer’s disease, their brains slowly accumulate abnormal clumps of two proteins: amyloid and tau. At ...

Nuclear cardiology is a specialised field in nuclear medicine that evaluates the heart function to help diagnosing conditions ...

A new biomarker test can detect early-stage tau protein clumping up to a decade before it appears on brain scans, improving ...

These various tests are at different stages of validation – assuring they’re accurate across many different populations. And, for each protein, there are several different met ...

Now, several publications and presentations at the recent Alzheimer’s Association International Conference have demonstrated that blood tests measuring amyloid and tau proteins have become much more ...

Researchers indicate that the Lumipulse p-tau217 assay may reduce over 50% of lumbar punctures performed for diagnosing ...

Alzheimer’s disease — which affects an estimated 7 million Americans — is notoriously difficult to detect, especially in its ...

LNTH READ THE FULL LNTH RESEARCH REPORT Lantheus Holdings, Inc. (NASDAQ:LNTH) began 2025 with a pair of potentially ...

Explore AC Immune's innovative Alzheimer's and Parkinson's therapies, key pharma collaborations, and financial outlook. Learn more on ACIU stock here.

Researchers have developed a test that spots early signs of Alzheimer's disease. Rather than looking for amyloid-beta plaques ...

Study finds that disease-modifying therapies for Alzheimer’s, lecanemab and donanemab, can extend independence in daily ...

在阿尔茨海默病（Alzheimer's disease，AD）的研究领域，一直存在着诸多谜团等待科学家们去解开。淀粉样蛋白 β（Amyloid-beta，Aβ）和 tau 蛋白的沉积，是 AD 的标志性病理特征 ，可这些病理变化往往在临床症状出现前许多年就已悄然开始。如今，针对 AD 的疾病修饰疗法，比如抗 Aβ 和抗 tau 抗体疗法不断涌现，这就使得在疾病的临床前期实现早期检测和精准预测 AD ...